Condition: Gastric Cancer · Hepatocellular Carcinoma · Non-Small-Cell Lung Cancer · Sponsor: Sichuan University
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.
This description comes directly from the study's public registry record.
Qiu Li · +86 028-85422589 · liqiu@scu.edu.cn
Always discuss trial participation with your own doctor first.
| Qiu Li | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04147078